HUTCHMED (HCM) Q2 2026 earnings review
Core Oncology Accelerates, While High Cash Balance Funds Ambitious Pipeline
At first glance, HUTCHMED's headline metrics look chaotic: flat overall revenue ($278.3M, +0.6% YoY) and a massive 96% drop in Net Income (to $15.9M). However, the earnings collapse is purely an optical illusion caused by the $477.5M pre-tax gain from the partial divestment of SHPL in 25H1. Operationally, the story is highly positive. Core oncology in-market sales are accelerating rapidly (+19% YoY), led by ELUNATE and SULANDA surging over 40% in China. While lower-margin distribution revenue is deliberately decelerating, the company's $1.37 billion cash pile provides a massive runway to fund its aggressive shift into first-in-class Antibody-Targeted Therapy Conjugates (ATTCs).
🐂 Bull Case
The 2025 streamlining of the China salesforce is yielding clear results. ELUNATE and SULANDA in-market sales grew 41% and 45% respectively, reflecting enhanced productivity and successful execution in targeting key hospitals.
With $1.37 billion in cash and short-term investments, HUTCHMED is fully insulated against near-term financing needs. This allows them to independently fund expensive global Phase I/II ATTC trials without dilutive equity raises.
🐻 Bear Case
Consolidated total revenue is stable at $278.3M (+0.6% YoY) only because a 14% decline in the Other Ventures segment offset the 13% growth in Oncology/Immunology. Shrinking distribution revenues will continue to act as a top-line drag.
Despite strong commercial progress, HUTCHMED's $15.9M net income was heavily reliant on an $18.1M regulatory milestone from Eli Lilly and $12.8M in interest and other income. Excluding these, the core business remains unprofitable amid rising R&D expenses.
⚖️ Verdict: 🟢
Bullish. The 96% drop in Net Income is noise driven by a prior-year asset sale. The real signal is the 33% drop in the cost of oncology revenues, >40% growth in domestic flagship drugs, and a bulletproof balance sheet to fund the next-gen pipeline.
Key Themes
Domestic Oncology Portfolio Accelerating
Following a restructuring of the commercial organization, China sales have re-accelerated. ELUNATE consolidated revenue jumped 40% to $47.1M, supported by National Reimbursement Drug List (NRDL) expansion into 2L endometrial cancer. SULANDA grew 45% to $18.4M after receiving an upgraded Level I recommendation in Chinese Society of Clinical Oncology guidelines. This proves the company's ability to drive penetration in established assets.
FRUZAQLA Global Rollout Gathering Steam
Partner Takeda is successfully expanding FRUZAQLA globally, with approvals or launches in 41 countries. Ex-US in-market sales surged approximately 70% to $68.9M. This geographical diversification is critical for insulating the company from single-market pricing pressures.
ATTC Platform Hits the Clinic
HUTCHMED is rapidly transitioning its Antibody-Targeted Therapy Conjugate (ATTC) pipeline into humans. HMPL-A251 (PI3K/PIKK-HER2) dosed its first patient in December 2025, and HMPL-A580 (PI3K/PIKK-EGFR) followed in March 2026. A third candidate, HMPL-A830, had its IND cleared in July. Replacing highly toxic traditional ADC payloads with targeted small molecules is a high-risk, high-reward strategy that could define the company's next decade.
FRUZAQLA Recognized Revenue Disconnect
A clear contradiction emerged regarding FRUZAQLA: while global in-market sales grew 14% to $185.4M, HUTCHMED's recognized consolidated revenue was completely flat at $43.1M. Management explained that growing royalties were offset by reduced manufacturing revenue from Takeda. As Takeda localizes or optimizes its supply chain, HUTCHMED's lower-margin manufacturing revenue shrinks, temporarily masking end-market demand growth.
Macro Pressures: FX and Distribution Pullback
The RMB depreciated by roughly 5% against the USD in H1 2026, creating a currency headwind for reported numbers (e.g., Oncology revenue grew 13% reported vs 10% Constant Exchange Rate). Concurrently, the Other Ventures distribution segment is decelerating (-14% to $116.0M) as management scales down low-margin logistics to optimize working capital.
R&D Spend Reversing Upward
R&D expenses increased 9% YoY to $78.8M. While entirely justified by the initiation of expensive global Phase I/II trials for ATTC candidates, it underscores that HUTCHMED is not yet a mature, self-sustaining commercial entity. Without the $18.1M milestone from Eli Lilly, operational losses would have widened.
Other KPIs
Accelerating improvement. Cost of revenue as a percentage of oncology product revenue dropped sharply from 39% in 25H1 to 33% in 26H1. This 600-basis-point expansion is a strong signal of manufacturing efficiencies and the successful scale-up of the new Shanghai drug product facility.
Stable. The company generated a positive $10.5M in operating and investing cash flow (excluding massive short-term investment reallocations and financing). While a steep drop from $519.1M in 25H1, the prior year included over $549M in net proceeds from the SHPL divestment. Underlying cash burn remains highly contained.
Guidance
Reversing. The reiterated full-year guidance midpoint of $390M implies a substantial ~36% YoY acceleration compared to the $285.5M generated in FY25. With $162.3M secured in H1, HUTCHMED needs roughly $228M in H2 to hit the midpoint, suggesting management expects a heavy back-half weighting, likely driven by late-year milestones or further commercial acceleration.
Key Questions
ATTC Partnership Strategy
With three ATTC candidates now moving into or through the clinic, what is the specific threshold of clinical data required before you seek to execute a multinational out-licensing partnership, similar to the Takeda deal for FRUZAQLA?
FRUZAQLA Economics
Consolidated FRUZAQLA revenue was flat YoY despite 14% end-market growth due to reduced manufacturing revenues from Takeda. Have we reached a run-rate floor for manufacturing revenues, and should we expect future quarters to mirror end-market royalty growth more closely?
Sovleplenib Commercial Prep
With NDAs accepted and under priority review for both ITP and wAIHA in China, what pre-commercialization investments are being made in H2 2026, and how will the salesforce be structured to handle non-oncology, hematology/immunology specialists?